Scholarlink

Background <p>To compare the efficacy, safety, and long-term clinical outcomes of LVIS and Enterprise stents in assisting coil embolization for ruptured intracranial aneurysms (RIAs) and to identify potential risk factors influencing surgical complications.</p> Methods <p>A retrospective analysis was conducted on prospectively collected data from a single center from December 2021 to June 2024. A total of 277 patients were initially screened; after excluding 77 patients using non-target stents, 95 patients were assigned to the LVIS group and 105 to the Enterprise group. Subsequently, 1:1 propensity score matching (PSM) was performed, resulting in 50 patients in each group to balance baseline characteristics.</p> Results <p>Before PSM, the LVIS group (<i>n</i> = 95) showed a marginally higher 1-year complete occlusion rate compared to the Enterprise group (100% vs. 98%, <i>P</i> = 0.046); however, this difference is based on only two events and should be interpreted with caution. After PSM, the risk of delayed cerebral ischemia (DCI) in the LVIS group was significantly higher than that in the Enterprise group (odds ratio [OR] 3.28, 95% confidence interval [CI] [1.01–10.69], <i>P</i> = 0.026). Both LVIS and Enterprise stents are safe and effective for assisting coil embolization in the treatment of RIAs.</p> Conclusions <p>The LVIS stent was associated with a marginally higher 1-year complete occlusion rate and a numerically lower recurrence rate, though this difference was supported by only two events (<i>P</i> = 0.046) and should be interpreted cautiously; it also carries a significantly greater risk of DCI after PSM.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Comparison of efficacy and safety of LVIS stents vs. enterprise stents in assisting coil embolization for ruptured intracranial aneurysms

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月20日

查看全文
  • Bingjing Tan,
  • Zongwu Li,
  • Zhizhong Wang,
  • Wenkang Lei,
  • Jianfeng Ye,
  • Jun Li

摘要

Background

To compare the efficacy, safety, and long-term clinical outcomes of LVIS and Enterprise stents in assisting coil embolization for ruptured intracranial aneurysms (RIAs) and to identify potential risk factors influencing surgical complications.

Methods

A retrospective analysis was conducted on prospectively collected data from a single center from December 2021 to June 2024. A total of 277 patients were initially screened; after excluding 77 patients using non-target stents, 95 patients were assigned to the LVIS group and 105 to the Enterprise group. Subsequently, 1:1 propensity score matching (PSM) was performed, resulting in 50 patients in each group to balance baseline characteristics.

Results

Before PSM, the LVIS group (n = 95) showed a marginally higher 1-year complete occlusion rate compared to the Enterprise group (100% vs. 98%, P = 0.046); however, this difference is based on only two events and should be interpreted with caution. After PSM, the risk of delayed cerebral ischemia (DCI) in the LVIS group was significantly higher than that in the Enterprise group (odds ratio [OR] 3.28, 95% confidence interval [CI] [1.01–10.69], P = 0.026). Both LVIS and Enterprise stents are safe and effective for assisting coil embolization in the treatment of RIAs.

Conclusions

The LVIS stent was associated with a marginally higher 1-year complete occlusion rate and a numerically lower recurrence rate, though this difference was supported by only two events (P = 0.046) and should be interpreted cautiously; it also carries a significantly greater risk of DCI after PSM.